The automated blood culture system is a medical device used to detect the presence of bacteria and other microorganisms in human blood. It is a vital tool in diagnosing patients with life-threatening infections such as sepsis. It also allows physicians to identify the source of the infection and develop precise treatment plans. This device helps improve clinical outcomes by providing timely diagnostic results within 12-16 hours. In addition, it reduces the cost of care by reducing test time and eliminating the need for blood cultures in many cases.
The BACT/ALERT VIRTUO system is the latest generation of continuous monitoring blood culture systems (CMBC) from bioMerieux. It is designed to detect the growth of organisms in bottles of blood and other sterile body fluids in a laboratory environment, and is compatible with most existing LIS systems. The system features intelligent, automated processes for specimen collection and processing, enabling users to focus on other tasks while improving lab productivity. It is also available in an ambulatory configuration for use in patient rooms and in other outpatient settings.
Compared with traditional plated medium methods, continuous-monitoring blood culture systems (CMBCS) can increase recovery of bacterial and fungal organisms from a wide range of sterile body fluid specimens, including hemodialysis vascular access infections. The ability to detect these organisms at an early stage can prevent progression to endocarditis, help patients avoid hospitalization, and improve clinical outcomes.
Although several CMBCS have been optimized for detecting BSI, they are currently not widely available in resource-limited settings (RLS) due to their high costs and unsuitable environmental conditions. Manufacturers from emerging economies are developing affordable in vitro diagnostics for BSI that may address these limitations; however, their potential effectiveness has not been demonstrated outside their home markets.
To evaluate the performance of these new, low-cost CMBCS, we compared the detection rates of BacT/Alert standard aerobic and anaerobic bottles with culture on routine media for six specimen types: continuous ambulatory peritoneal dialysis (CAPD), amniotic, peritoneal, pleural, and synovial fluids. We found that in most of the six specimen types, BacT/Alert achieved comparable or better detection rates than culture on routine media and had a higher number of significant isolates than plated medium methods.
In our pilot study with a limited number of spiked samples, we found that all four CMBCS systems accepted the Autobio and DL-Biotech BCBs interchangeably (Table 6). The interchangeability of these two BCBs is likely due to their baseline color and a similar evaluation of color change.
The report provides a global view of the Automated Blood Culture System market with production, revenue, price, gross margin, and consumption broken down by application and region. Chapter 1 gives a full-scale analysis of the competition between key players in the industry. It includes their market share, production, revenue, price, gross margin, product introduction, and recent development. Chapter 2 focuses on the global market of Automated Blood Culture System, with production, revenue, price, gross margin, sales and regional share broken down by type, application and region.